NCT00825058 - Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine | Biotech Hunter

Enrollment

317

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

May 31, 2004

Study Completion Date

October 31, 2004

Conditions

Major Depressive Disorders

Interventions

DRUG

amibegron (SR58611A)

oral administration 2 X 350mg/day at 12 hours intervals

DRUG

placebo

oral administration 12 hours intervals

DRUG

paroxetine

oral 20 mg/day

Trial Locations (8)

Sanofi-Aventis Administrative Office, Sofia

Sanofi-Aventis Administrative Office, Zagreb

Sanofi-Aventis Administrative Office, Prague

Sanofi-Aventis Administrative Office, Tallinn

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Montenegro

Sanofi-Aventis Administrative Office, Gouda

Sanofi-Aventis Administrative Office, Belgrade